Quantcast

Latest Thrombocytopenia Stories

2010-11-22 19:11:34

Skin cells from humans can be revamped into pro-clotting cells called platelets, according to a study published on November 22 in the Journal of Experimental Medicine (www.jem.org). Patients with diseases causing thrombocytopenia"”platelet deficiency"”often require repeated transfusions with platelets obtained from healthy donors. But donor platelet isolation is expensive and labor intensive, and donor platelets can be attacked by the patient's immune systems as "foreign."...

2010-11-11 18:35:44

Study first to show that drug reduces risk of dangerous bleeding, need for spleen removal A new study finds that an FDA-approved drug to treat the rare autoimmune disorder immune thromobocytopenia (ITP) is more effective than earlier medical therapies in helping patients avoid surgical treatment and significantly improving their quality of life. The paper in the Nov. 11 New England Journal of Medicine reports that treatment with romiplostim, which mimics the effects of a growth factor that...

2010-11-10 16:04:00

THOUSAND OAKS, Calif., Nov. 10, 2010 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced the publication of results from the first open-label study to compare Nplate(® )(romiplostim) treatment to standard of care therapies (SOC) in non-splenectomized adult patients with chronic immune thrombocytopenia (ITP). The study results, which were published today in the New England Journal of Medicine (NEJM), show that both the incidence of treatment failure and need...

2010-10-27 10:00:00

(Ivanhoe Newswire) -- Platelets are cell fragments that circulate in the blood of mammals.  These big, regularly-shaped cells are chiefly involved in hemostasis, a central factor leading to the formation of blood clots.  If the number of platelets is too low, excessive bleeding can occur (thrombocytopenia).  However, if the number of platelets is too high, blood clots can form (thrombosis). Mortimer Poncz and colleagues, at Children's Hospital of Philadelphia, working with...

2010-10-14 09:22:00

RESEARCH TRIANGLE PARK , N.C., Oct. 14 /PRNewswire-FirstCall/ -- Talecris Biotherapeutics (Nasdaq: TLCR) announced today that the U.S. Food and Drug Administration (FDA) approved Gamunex®-C (Immune Globulin Injection [Human], 10% Caprylate/Chromatography Purified) for subcutaneous administration in the treatment of primary immunodeficiency (PI). The newly approved Gamunex-C provides both the intravenous route of administration and a new subcutaneous route of...

2010-09-23 18:30:00

BEDFORD, Mass., Sept. 23 /PRNewswire/ -- Instrumentation Laboratory (IL), today announced it will host the 2nd IL Asia Pacific Hemostasis Forum on Wednesday, October 13, 2010 at the Grand Hyatt Nusa Dua, in Bali, Indonesia. The event will run from 8:00 am to 12:00 pm, local time. The forum will focus on the latest clinical and diagnostic advances and trends in hemostasis. All healthcare professionals, practicing in the Asia Pacific region are welcome to attend. Professor Karmel...

2010-07-26 07:30:00

BEDFORD, Mass., July 26 /PRNewswire/ -- Instrumentation Laboratory (IL), today announced it will host an ILluminations webinar on HIT, to be held on Thursday, October 7, 2010 from 2:00 p.m. to 3:00 p.m. (Central European Time). This web-based, Continuing Education seminar will feature Andreas Greinacher, M.D., presenting "Laboratory and Clinical Aspects of HIT." The essential components for successful implementation and management of a HIT testing program will be discussed. HIT is a...

2010-06-17 16:34:00

Approval expands use in treatment of rare type of leukemia SILVER SPRING, Md., June 17 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved a new indication for Tasigna (nilotinib) for the treatment of a rare blood cancer when it is first diagnosed. The cancer, called Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML), is a slowly progressing blood and bone marrow disease linked to a genetic abnormality. (Logo:...

2010-04-20 17:39:00

Readers are referred to the cautionary notes regarding Forward-looking information at the end of this release Listed TSX, Symbol: CNJ TORONTO and WINNIPEG, April 20 /PRNewswire-FirstCall/ - Cangene Corporation today reports that it has signed a new agreement with Baxter Healthcare Corporation under which Cangene assumes the commercialization rights to WinRho(R) SDF (Rho(D) Immune Globulin Intravenous (Human)) for the U.S. market. Cangene and Baxter have mutually agreed to terminate an...

2010-04-19 07:31:00

KING OF PRUSSIA, Pa., April 19 /PRNewswire/ -- CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) to extend the shelf life for Privigen®, Immune Globulin Intravenous (Human), 10% Liquid, from 24 to 36 months. The approval makes Privigen the first liquid intravenous immunoglobulin (IVIg) in the U.S. that can be stored at room temperature throughout its entire 36-month shelf life....


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related